Literature DB >> 2260171

Long-term follow-up of patients with Leishmania (Viannia) braziliensis infection and treated with Glucantime.

E M Netto1, P D Marsden, E A Llanos-Cuentas, J M Costa, C C Cuba, A C Barreto, R Badaró, W D Johnson, T C Jones.   

Abstract

Seventy-nine patients with cutaneous (62) or mucosal (17) infection with Leishmania (Viannia) braziliensis in Três Braços, Bahia, Brazil, were followed for at least 4 years after initiating treatment with antimony. Cutaneous relapses occurred in 6/62 (10%), mucosal relapse after cutaneous infection in 2/62 (3%), and mucosal relapse after mucosal disease in 2/17 (17%). It is concluded that relapse (cutaneous and mucosal) is rare after adequate antimony therapy and that no definite prediction of relapse (clinical, serological or by skin reaction) is possible.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2260171     DOI: 10.1016/0035-9203(90)90321-5

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  13 in total

1.  Eligibility for Local Therapies in Adolescents and Adults with Cutaneous Leishmaniasis from Southwestern Colombia: A Cross-Sectional Study.

Authors:  Andrés Felipe Uribe-Restrepo; Miguel Dario Prieto; Alexandra Cossio; Mayur M Desai; María Del Mar Castro
Journal:  Am J Trop Med Hyg       Date:  2019-02       Impact factor: 2.345

Review 2.  Therapeutic options for old world cutaneous leishmaniasis and new world cutaneous and mucocutaneous leishmaniasis.

Authors:  Begoña Monge-Maillo; Rogelio López-Vélez
Journal:  Drugs       Date:  2013-11       Impact factor: 9.546

3.  Decreased in situ expression of interleukin-10 receptor is correlated with the exacerbated inflammatory and cytotoxic responses observed in mucosal leishmaniasis.

Authors:  Daniela R Faria; Kenneth J Gollob; José Barbosa; Albert Schriefer; Paulo R L Machado; Hélio Lessa; Lucas P Carvalho; Marco Aurélio Romano-Silva; Amélia R de Jesus; Edgar M Carvalho; Walderez O Dutra
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

4.  Cutaneous leishmaniasis in travellers: a focus on epidemiology and treatment in 2015.

Authors:  Adrienne J Showler; Andrea K Boggild
Journal:  Curr Infect Dis Rep       Date:  2015-07       Impact factor: 3.725

5.  Type I interferons induced by endogenous or exogenous viral infections promote metastasis and relapse of leishmaniasis.

Authors:  Matteo Rossi; Patrik Castiglioni; Mary-Anne Hartley; Remzi Onur Eren; Florence Prével; Chantal Desponds; Daniel T Utzschneider; Dietmar Zehn; Maria G Cusi; F Matthew Kuhlmann; Stephen M Beverley; Catherine Ronet; Nicolas Fasel
Journal:  Proc Natl Acad Sci U S A       Date:  2017-04-24       Impact factor: 11.205

Review 6.  Leishmaniases of the New World: current concepts and implications for future research.

Authors:  G Grimaldi; R B Tesh
Journal:  Clin Microbiol Rev       Date:  1993-07       Impact factor: 26.132

7.  Molecular, cytological, and immunocytochemical study and kDNA sequencing of laryngeal Leishmania infantum infection.

Authors:  Ahmad Oryan; Sadegh Shirian; Mohammad Reza Tabandeh; Gholam Reza Hatam; Mohsen Kalantari; Yahya Daneshbod
Journal:  Parasitol Res       Date:  2012-12-24       Impact factor: 2.289

8.  Association between HLA genes and American cutaneous leishmaniasis in endemic regions of Southern Brazil.

Authors:  Rejane C Ribas-Silva; Adriana D Ribas; Maria C G Dos Santos; Waldir V da Silva; Maria V C Lonardoni; Sueli D Borelli; Thaís G V Silveira
Journal:  BMC Infect Dis       Date:  2013-05-02       Impact factor: 3.090

9.  In Vitro Antiparasitic and Apoptotic Effects of Antimony Sulfide Nanoparticles on Leishmania infantum.

Authors:  Saied Soflaei; Abdolhossein Dalimi; Fatemeh Ghaffarifar; Mojtaba Shakibaie; Ahmad Reza Shahverdi; Mohsen Shafiepour
Journal:  J Parasitol Res       Date:  2012-06-26

10.  Antigen-triggered interferon-γ and interleukin-10 pattern in cured mucosal leishmaniasis patients is shaped during the active phase of disease.

Authors:  R S Nogueira; A Gomes-Silva; R C Bittar; D Silva Mendonça; V S Amato; M da Silva Mattos; M P Oliveira-Neto; S G Coutinho; A M Da-Cruz
Journal:  Clin Exp Immunol       Date:  2014-09       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.